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PMINI-FOCUS: CELL-BASED THERAPY
Myogenic Endothelial Cells Purified From
Human Skeletal Muscle Improve Cardiac Function
After Transplantation Into Infarcted Myocardium
Masaho Okada, MD,*‡ Thomas R. Payne, PHD,*‡ Bo Zheng, MD,*‡ Hideki Oshima, MD, PHD,*‡
Nobuo Momoi, MD,† Kimimasa Tobita, MD,† Bradley B. Keller, MD,† Julie A. Phillippi, PHD,*¶
Bruno Péault, PHD,*† Johnny Huard, PHD*‡§
Pittsburgh, Pennsylvania
Objectives The aim of this study was to evaluate the therapeutic potential of human skeletal muscle-derived myoendothe-
lial cells for myocardial infarct repair.
Background We have recently identified and purified a novel population of myoendothelial cells from human skeletal muscle.
These cells coexpress myogenic and endothelial cell markers and produce robust muscle regeneration when
injected into cardiotoxin-injured skeletal muscle.
Methods Myoendothelial cells were isolated from biopsies of human skeletal muscle using a fluorescence-activated cell
sorter along with populations of regular myoblasts and endothelial cells. Acute myocardial infarction was in-
duced in male immune-deficient mice, and cells were directly injected into the ischemic area. Cardiac function
was assessed by echocardiography, and donor cell engraftment, angiogenesis, scar tissue, endogenous cardio-
myocyte proliferation, and apoptosis were all evaluated by immunohistochemistry.
Results A greater improvement in left ventricular function was observed after intramyocardial injection of myoendothe-
lial cells when compared with that seen in hearts injected with myoblast or endothelial cells. Transplanted
myoendothelial cells generated robust engraftments within the infarcted myocardium, and also stimulated an-
giogenesis, attenuation of scar tissue, and proliferation and survival of endogenous cardiomyocytes more effec-
tively than transplanted myoblasts or endothelial cells.
Conclusions Our findings suggest that myoendothelial cells represent a novel cell population from human skeletal muscle
that may hold promise for cardiac repair. (J Am Coll Cardiol 2008;52:1869–80) © 2008 by the American
College of Cardiology Foundation
ublished by Elsevier Inc. doi:10.1016/j.jacc.2008.07.064s
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mhe number of patients suffering from severe heart failure
fter myocardial infarction (MI) is increasing in Western
ountries. As an alternative to heart transplantation, cellular
ardiomyoplasty is a promising new approach for preventing
dvanced heart failure and restoring cardiac function in
njured hearts. Researchers have investigated a variety of cell
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ccepted July 21, 2008.ources for cardiac repair (1–6). Initial studies in cell
herapy for cardiac repair used committed skeletal myoblasts
SkMs), largely because they can be readily harvested and
asily expanded in vitro before autologous transplantation.
See page 1881
owever, high cell death rates were reported shortly after
kMs injection in both cardiac and skeletal muscles
7–11), which has hindered the therapeutic usefulness of
kMs. Many subsequent attempts have been made to
dentify and isolate alternative stem cells or progenitors
rom skeletal muscle that could have a greater capacity for
ost-transplantation cell survival and muscle regeneration
12).
We have previously isolated a population of skeletal
uscle-derived stem cells (MDSCs) that adhere morelowly to culture flasks than committed SkMs after enzy-
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Cardiomyoplasty Via Human Stem Cells December 2, 2008:1869–80matic dissociation of murine
skeletal muscle (13). When in-
jected into the myocardium of
infarcted hearts, MDSCs dis-
played excellent survival and en-
graftment, induced angiogenesis,
and improved left ventricular
(LV) function in a more effective
manner when compared with
that seen with the transplan-
tation of SkMs (14). This dis-
tinct difference between mouse
SkMs and MDSCs for MI re-
pair indicated that skeletal
muscle-derived progenitor cells
are heterogeneous in therapeu-
tic efficacy.
Although murine MDSCs
display many characteristics asso-
ciated with the myogenic lineage,
these cells also have attributes
typically associated with the en-
dothelial lineage. Upon isolation,
MDSCs expressed CD34, a
marker characteristic of endothe-
lial progenitor cells. In addition,
these cells differentiated into en-
dothelial cells and promoted an-
giogenesis either upon stimula-
tion with vascular endothelial
growth factor (VEGF) in culture
or after transplantation into skel-
etal and cardiac muscles (13–15).
Studies published by other inves-
tigators have documented the
presence of myogenic progenitor
cells that coexpress markers asso-
iated with the myogenic and endothelial lineages in the
nterstitial spaces of adult mouse skeletal muscle and in the
orsal aorta of mouse embryos (16,17). Together, these
ndings led us to the recent identification and isolation of
rogenitor cells residing within adult human skeletal muscle
hat also coexpress myogenic and endothelial cell markers (18).
ransplantation of these myoendothelial cells into the injured
keletal muscles of immunodeficient mice resulted in consid-
rably more de-novo myofibers when compared with that seen
ith the injection of conventional myogenic and endothelial
ells (18).
Here, we investigated the therapeutic potential of myoen-
othelial cells for cardiac repair using an acute MI model
reated in immunodeficient mice. We show that myoendothe-
ial cells provided greater therapeutic benefit after MI than did
ndothelial cells, myogenic cells, and unsorted myoblasts. This
herapeutic advantage may be collectively attributed to the high
egenerative, angiogenic, antifibrotic, and cardio-protective
Abbreviations
and Acronyms
cTnI  cardiac-specific
isoforms of troponin I
cTnT  cardiac-specific
isoforms of troponin T
DMEM  Dulbecco’s
modified Eagle’s medium
EDA  end-diastolic area
ELISA  enzyme-linked
immunoadsorbent assay
FAC  fractional area
change
FACS  fluorescence-
activated cell sorting
FBS  fetal bovine serum
fskMyHC  fast skeletal
myosin heavy chain
LV  left
ventricle/ventricular
MDSC  muscle-derived
stem cell
MI  myocardial infarction
nLacZ  nuclear LacZ
PBS  phosphate-buffered
saline
PCNA  proliferating cell
nuclear antigen
qPCR  quantitative real-
time polymerase chain
reaction
SkM  skeletal myoblast
TUNEL  terminal dUPT
nick end-labeling
VEGF  vascular
endothelial growth factornd -stimulatory effects of myoendothelial cells. Bethods
uman skeletal muscle cell isolation. The procurement
f human skeletal muscle biopsies (male subject, 21 and 23
ears old, female subject, 26 years old) from The National
isease Research Interchange was approved by the Institu-
ional Review Board at the University of Pittsburgh Medical
enter. The human skeletal muscle biopsies were placed in
olution with Hank’s balanced salt solution and were trans-
orted to the laboratory on ice.
The human skeletal muscle biopsy was finely minced, and
hen digested for 60 minutes at 37°C with type I and type
V collagenase (100 /ml) and dispase (1.2 /ml; all from
IBCO, Invitrogen Corp., Carlsbad, California). The di-
ested tissue was pelleted and resuspended in Dulbecco’s
odified Eagle’s medium (DMEM, GIBCO) supple-
ented with 10% (v/v) fetal bovine serum (FBS, GIBCO)
nd 1% (v/v) penicillin/streptomycin. The pellet was then
nzymatically dissociated, and passed through a 40-m
lter to obtain a single-cell suspension. Approximately 7 
05 cells were recovered per gram of tissue.
We used fluorescence-activated cell sorting (FACS) to
solate various cell fractions based on their expression of the
ell surface markers CD56, CD34, and CD144, as previ-
usly described (18). We also used an unpurified (unsorted)
ell population as a control experiment. Briefly, the cell
ellet was suspended in DMEM that was supplemented
ith 2% FBS. The cell solution was then incubated on ice
ith allophycocyanin (APC)-Cy7-conjugated mouse anti-
uman CD45, APC-conjugated mouse antihuman CD34,
hycoerythrin (PE)-Cy7-conjugated mouse antihuman
D56 (all from BD Biosciences, San Jose, California), and
E-conjugated mouse antihuman CD144 (Beckman
oulter, Fullerton, California). Isotype control antibodies
ere APC-Cy7-, APC-, PE-Cy7-, and PE-conjugated
ouse IgG1 (all from BD Biosciences); 7-amino-
ctinomycin D (7-AAD, ViaProbe; BD Pharmingen, San
ose, California) was added to each tube for dead cell
xclusion. Background staining was evaluated with isotype-
atched control antibodies and a CompBeads set (Becton-
ickinson, San Jose, California) was used to optimize
uorescence compensation settings for multicolor analyses
nd sorts. A minimum of 1  105 live cell events were
nalyzed using a FACSCalibur flow-cytometer (Becton-
ickinson) and the CellQuest software (Becton-
ickinson). Cell sorting was performed on a FACSAria
ual-laser fluorescence cell sorter (Becton-Dickinson).
orted cells were reanalyzed in all experiments. For this
tudy,wecollectedthefollowingpopulations:CD56CD34
D144, CD56CD34CD144, and CD56CD34
D144. The 3 sorted cell populations were plated in
ollagen-coated 96-well plates at a density of 500 cells per
ell in proliferation medium consisting of DMEM, 10%
v/v); FBS, 10% (v/v); horse serum, 1% (v/v); penicillin/
treptomycin, 1% (v/v); and chick embryo extract (GIBCO-
RL, Carlsbad, California) and incubated at 37°C in a 5%
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December 2, 2008:1869–80 Cardiomyoplasty Via Human Stem CellsO2 atmosphere. At 70% confluence, cells were passage
issociated with trypsin/EDTA (GIBCO-BRL), replated
t a cell density of 1.0 to 2.5  103 cells/cm2 and cultured
or 3 to 4 weeks before intracardiac transplantation. To
rack donor cell fate after injection, we transduced myoen-
othelial cells with a retrovirus encoding for a nuclear LacZ
nLacZ) reporter gene as previously described (15,18).
ntramyocardial cell transplantation into an acute
I. The Institutional Animal Care and Use Committee,
hildren’s Hospital of Pittsburgh, approved the animal and
urgical procedures performed in this study (Protocol 37/
4). A total of 74 male nonobese diabetic severe combined
mmunodeficiency (NOD/SCID) mice (The Jackson Lab-
ratory, Bar Harbor, Maine) were used for this study.
verall, 5 animals died during surgery, resulting in a 6.8%
perative mortality. One animal was excluded from this
tudy due to the presence of a thymic lymphoma, which is
nown to naturally occur on occasion in this mouse strain
19). Infarcted mice were randomly allocated between the
ypes of treatment (saline, CD56CD34CD144, CD56
D34CD144, and CD56CD34CD144 cells) for
ach donor. The 3 sorted cell populations and unsorted cells
ere injected (3  105 cells in a solution of 30 l of
hosphate-buffered saline [PBS] per heart) into the hearts
f mice immediately after inducing MI as previously de-
cribed (14). In control mice, 30 l of PBS alone was
njected. The investigator creating the infarction injury and
njecting the cells was blinded to the contents of the
njectant. Histological and functional studies were per-
ormed at 5 days and 2 and 6 weeks post-transplantation
n  14 animals sacrificed at 5 days, 25 animals sacrificed
t 2 weeks, and 29 animals sacrificed at 6 weeks).
chocardiography was performed by a blinded investiga-
or to assess the heart function of anesthetized mice, as
reviously described (14).
istological analysis. The mice were sacrificed at 5 days, 2
eeks, and 6 weeks after cell transplantation for histological
valuation of the heart tissue. Hearts were flash frozen in
-methylbutane (Sigma-Aldrich, St. Louis, Missouri) that
as pre-cooled in liquid nitrogen. For immunohistochem-
cal assays, some excised hearts were fixed in 10% formalin
y perfusion from the ascending aorta and embedded in
araffin.
To detect proliferating human cells, cryosections were
ncubated with human antihuman proliferating cell nuclei
ntigen (PCNA, 1:400, US Biological, Swampscott, Mas-
achusetts) at room temperature for 2 h followed by the
ddition of goat antihuman IgG 555 (1:800, Molecular
robes, Eugene, Oregon). Then, the sections were
ostained for fast skeletal myosin heavy chain (fskMyHC) as
escribed previously (14,15). Sections containing the high-
st number of fibers expressing fskMyHC were used, for
ach group, to determine a regeneration index, defined as
he number of fskMyHC-positive fibers per section (14,15).
For immunofluorescent human VEGF staining, cryosec-
ions were incubated with Xgal substrate for 2 h and Mncubated overnight at 4°C with a goat antihuman VEGF
1:100, R&D Systems, Minneapolis, Minnesota), followed
y incubation with a donkey antigoat IgG 555 (1:200,
olecular Probes).
To determine whether donor cells expressed cardiac cell
arkers, tissue samples were incubated with Xgal substrate
or 2 h. Then the sections were incubated with mouse
ntihuman cardiac troponin T (1:50, Abcam, Cambridge,
assachusetts), followed by donkey-antimouse IgG 488
1:400, Molecular Probes). Alternatively, Xgal-stained
lides were incubated with anticardiac troponin I at room
emperature for 2 h followed by the addition of donkey
ntigoat IgG 555 (1:200, Molecular Probes). To determine
apillary density within the infarct zone, we performed
mmunostaining of CD31 on cryosections and measured
apillary density within the infarct region of each heart, as
reviously described (14).
For Ki-67 immunohistochemical staining, deparaffinized
ections were immersed in preheated sodium citrate buffer
nd were incubated overnight at 4°C with a rat monoclonal
ntimouse Ki-67 antibody (1:50, DAKO, Carpinteria, Cal-
fornia) that does not cross-react with human Ki-67. Posi-
ive reactivity was determined with Vectastain Elite ABC
it (Vector Laboratories, Burlingame, California) and vi-
ualized as purple with the VIP (violet-colored precipitate)
ubstrate kit (Vector Laboratories). To determine the num-
er of proliferating myocytes, tissues were counterstained
ith anticardiac troponin I (cTnI) (1:20,000, Scripps, San
iego, California), processed with Vectastain Elite ABC
it (Vector Laboratories), and then visualized as brown
hrough the DAB (3,3=-diaminobenzidine) substrate kit
Vector Laboratories). The number of mitotically active
ndogenous cardiomyocytes within the peri-infarct region
as measured in 8 high-power fields (400 magnification).
For terminal dUPT nick end-labeling (TUNEL) stain-
ng, the deparaffinized sections were digested with pro-
einase K according to the protocols provided by manufac-
urer (ApopTag Plus Peroxidase In Situ Apoptosis
etection Kit; Chemicon, Temecula, California). The
UNEL stain was visualized with a substrate system that
tained purple (VIP substrate kit; Vector Laboratories). The
amples were also lightly counterstained with anti-cTnI as
escribed in the preceding text with the Ki-67 stain. The
umber of apoptotic endogenous cardiomyocytes within the
eri-infarct region was measured in 4 high-power fields
400 magnification) (20).
For human-specific VEGF immunohistochemical stain-
ng, deparaffinized sections were immersed in preheated
odium citrate buffer and were incubated overnight at 4°C
ith a goat antihuman VEGF (1:50, R&D Systems). The
lides were then processed with Vectastain Elite ABC Kit
Vector Laboratories). A positive stain was visualized as
rown using the DAB substrate kit (Vector Laboratories).
hese sections were counterstained with eosin.
We used Masson’s trichrome staining kit (IMEB, San
arcos, California) to stain collagen deposition on frozen
c
a
u
o
c
m
H
h
a
s
(
p
f
d
t
(
d
P
C
a
7
t
U
a
I
H
r
a
H
r
a
H
r
a
H
r
a
k
s
B
(
c
c
S
m
m
s
t
e
V
a
c
p
f
a
d
p
w
m
c
o
S
C
R
C
o
y
a
e
(
e
l
o
C
C
T
p
C
c
P
8
m
e
u
t
t
e
T
C
C
M
l
e
1872 Okada et al. JACC Vol. 52, No. 23, 2008
Cardiomyoplasty Via Human Stem Cells December 2, 2008:1869–80ryosections of the heart. The area of infarct scar and the
rea of the entire cardiac muscle section were measured
sing a digital image analyzer (Image J, National Institutes
f Health, Bethesda, Maryland). The scar area fraction was
alculated as the ratio of scar area to the entire cardiac
uscle area and was averaged from 7 sections per heart.
ypoxia assay. We cultured all 3 cell populations under
ypoxic conditions (2.5% O2) in vitro and measured the
mount of VEGF that was secreted into the cell culture
upernatant by enzyme-linked immunoadsorbent assay
ELISA) (R&D Systems, Minneapolis, Minnesota), as
reviously described (21). Total RNA (n  3) was extracted
rom cell lysates using an RNeasy kit with DNase I
igestion (Qiagen, Valencia, California). After RNA ex-
raction, quantitative real-time polymerase chain reaction
qPCR) analysis was carried out as 10-l reactions as
escribed previously (22,23) using TaqMan One-Step RT-
CR Master Mix (Applied Biosystems Inc., Foster City,
alifornia) and 1 l total RNA as the template. qPCR
ssays were carried out in triplicate on an ABI Prism
900HT sequence detection system in the core facility of
he Genomics and Proteomics Core Laboratories of the
niversity of Pittsburgh. Sequences for target gene primers
nd probes (IDT-Integrated DNA Technologies, Coralville,
owa) were as follows:
uman Vegf165 (NM 001033756): forward: 5= CATGCA-
GATTATGCGGATCAA 3=;
everse: 5= TTTGTTGTGCTGTAGGAAGCTCAT 3=;
nd TaqMan probe: 5= CCTCACCAAGGCCAGCAC-
ATAGGAGA 3=
uman Igf-I (X57025): forward: 5=TGTATTGCGCA-
CCCCTCAA3=;
everse: 5=TGCGTTCTTCAAATGTACTTCCTT3=;
nd TaqMan probe: 5= CAGCTCGCTCTGTCCGTG-
CCC 3=
uman Hgf (X 16323): forward: GAGGCCATGGTGC-
TATACTCTTG;
everse: TCAGCGCATGTTTTAATTGCA;
nd TaqMan probe: CCCTCACACCCGCTGGGAGTA
(5= 6FAM and 3= TAMRA-Sp)
uman b-Fgf (NM 002006): forward: GGCGTGTA-
CATGTGGTCTCAGA;
everse: TTATGGCTCACTGCAACCTTGA;
nd TaqMan probe: AAGTGATCAACCCTCCCACC-
TCAGCCT (5= 6FAM 3= TAMRA-Sp)
All target genes were normalized to the reference house-
eeping gene 18S (Applied Biosystems Inc.). Gene expres-
ion levels were analyzed using SDS 2.2 Software (Applied
iosystems Inc.) and were calculated as total amount RNAin arbitrary fluorescence units) compared with negative control levels (normal O2) for each time point based on the
omparative CT method (separate tubes) (24).
tatistical analysis. All measured data are presented as
ean  standard error. Kaplan-Meier survival curve esti-
ation with log-rank test was performed to compare the
urvival rate among experimental groups. For the analysis of
he echocardiographic data, the scar tissue area data, the
ndogenous cardiomyocyte proliferation data, and the
EGF qPCR and ELISA data, we applied the 2-way
nalysis of variance (ANOVA) test and the Tukey multiple
omparison test. The 1-way ANOVA and the Tukey
ost-hoc tests were performed to analyze the number of
skMyHC-expressing myocytes and capillary density data in
ll groups. For the endogenous cardiomyocyte apoptosis
ata, we applied the Kruskal-Wallis and the Dunn’s multi-
le comparison tests at each time point. The Student t test
as performed for the Vegf and Hgf gene expression data in
yoendothelial cells cultured under normoxic and hypoxic
ulture conditions. Statistical significance was set at a value
f p  0.05. All statistical tests were performed using
igmaStat (Systat Software Inc., Point Richmond,
alifornia).
esults
ell isolation by FACS. Cells were isolated from 3 samples
f adult human skeletal muscle (first subject, male, age 21
ears; second subject, male, age 23 years; third subject, female,
ge 26 years) by FACS on the basis of their differential
xpression of the myogenic (CD56) and endothelial cell
CD34 and CD144) surface markers (18). CD45 was used to
xclude hematopoietic cells (18). The fraction of myoendothe-
ial cells (CD56CD34CD144CD45) represented 1.8%
f the total cell population, while endothelial cells (CD56
D34CD144CD45) and myogenic cells (CD56CD34
D144CD45) accounted for 9.0% and 2.6%, respectively.
he mean numbers of viable sorted cells that were recovered
er experiment were 9.6  104 CD56CD34CD144
D45 cells, 45.8  104 CD56CD34CD144CD45
ells, and 8.8  104 CD56CD34CD144CD45 cells.
urities of these 3 sorted cell populations were, respectively,
9.1%, 92.8%, and 81.1%, as confirmed by flow reanalysis. The
yogenic, endothelial, and myoendothelial cell isolates were
xpanded in culture before intramyocardial transplantation,
sing a protocol previously described (18).
We have previously evaluated the myogenic and endo-
helial cell phenotype of sorted cells after cultivation using
he myogenic marker CD56 and the endothelial cell mark-
rs CD146 and Ulex europeaus agglutinin 1 receptor (18).
he phenotype of the sorted endothelial cells (CD56
D34CD144) and myoendothelial cells (CD56CD34
D144) changed after expansion in tissue culture flasks.
yogenic cells (CD56CD34CD144) retained a high
evel of CD56 expression, but a portion of cells also
xpressed CD146 after cultivation. Interestingly, 65% of
ultured endothelial cells expressed CD56 even though this
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December 2, 2008:1869–80 Cardiomyoplasty Via Human Stem Cellsopulation was 92.8% pure (CD56CD34CD144) after
ACS isolation. A large portion of cultured myoendothelial
ells retained a myogenic and endothelial cell phenotype.
xpression of Ulex europeaus agglutinin 1 receptor was low
n all cell types.
ardiac repair. The therapeutic effect of myogenic, endo-
helial, and myoendothelial cells for cardiac repair was
ssessed in an immunodeficient mouse model of an acute
I. Over the course of this study, we did not observe a
ignificant difference in survival rates among the groups (p
0.13; Kaplan-Meier survival curve) (Fig. 1A). In unin-
ured NOD/SCID mice (age 12 weeks, weight 27.2 
.4 g), we have measured baseline LV dimensions and
unction by echocardiography. Baseline end-diastolic area
EDA) of uninjured mice (n  5 mice) was 9.3  0.3 mm2
Fig. 1B), and baseline fractional area change (FAC) was
6.4  1.5% (n  5) (Fig. 1C). The hearts in all 3 cell
roups had smaller LV dimensions, as assessed by EDA
Fig. 1B) and end-systolic area (data not shown), when
ompared with those in the control group, which consisted
f PBS injections into the heart. Compared with baseline
ninjured hearts and control PBS-injected hearts (12.2 
.5 mm2), hearts that received intracardiac injections of
yoendothelial cells (9.6  0.8 mm2) tended to preserve
V dimensions at 2 weeks after cell transplantation. How-
ver, by 6 weeks, the LV expanded in hearts injected with
yoendothelial cells (12.6  0.8 mm2), and was only
lightly less than PBS-injected hearts in size (13.8  1.7
m2) (Fig. 1B).
LV contractility, as determined by FAC values, improved
0% and 17% at 2 and 6 weeks after MI, respectively, in the
yogenic group (2 weeks: FAC 19.6  2.9%, 6 weeks: 18.5
2.4%) compared with that seen in the control PBS group
2 weeks: 16.4  2.6%, 6 weeks: 15.9  3.1%) (Fig. 1C).
ransplanted endothelial cells (2 weeks: 23.4  1.4%, 6
eeks: 19.0 1.9%) improved systolic function by 47% and
5% at 2 and 6 weeks, respectively, compared with control
njections of PBS (Fig. 1C). In comparison to the other 2
ell groups, LV contractility was the strongest in the
yoendothelial group (2 weeks: 30.0 3.0%, 6 weeks: 27.8
3.3%) resulting in FAC values that were 84% and 75%
reater than those in the control PBS group at the 2 and 6
eek time points, respectively (Fig. 1C) (p  0.05, myoen-
othelial cells vs. myogenic cells and PBS).
We performed injections using unsorted human myo-
lasts isolated from the same donor (Figs. 1D and 1E). No
ifference in LV dimensions was observed between the
nsorted myoblasts (EDA: 11.7  0.6 mm2) and sorted
D56myogenic cells (11.5 0.5 mm2) (Fig. 1D). Hearts
njected with unsorted human myoblasts displayed poor LV
ontractility (FAC: 18.3  2.1%) at 2 weeks after MI,
hich was comparable to hearts injected with the sorted
D56 myogenic cell population (CD56CD34
D144, FAC 19.6  2.9%) (Fig. 1E).
Injection of all 3 sorted cell populations was repeatedsing cell isolates from another donor (male, 21 years old). egain, hearts injected with myoendothelial cells (FAC: 37.4
1.9%) displayed the strongest LV contraction compared
ith that in the other groups at 2 weeks after MI (p 0.05,
yoendothelial cells vs. myogenic cells, endothelial cells,
nd control PBS). In comparison to the injection of PBS
nly (23.0 1.9%), cardiac contractility improved 62% with
he injection of myoendothelial cells, 28% with the injection
f endothelial cells (28.7 2.8%), and 7% with the injection
f myogenic cells (24.6  1.3%).
car tissue formation. The extent of scar tissue formation
ithin the infarcted area was evaluated using Masson’s
richrome stain (Fig. 2A). At both time points (2 weeks and
weeks), LV infarct scar area was smaller, as determined by
car area fraction values, in all 3 cell groups when compared
ith the control PBS group, with the most notable im-
rovement occurring at the 6 week time point (Fig. 2B).
earts injected with myoendothelial cells exhibited less scar
issue than those injected with PBS 2 and 6 weeks after
nfarction (p  0.05, myoendothelial cells vs. PBS) (Fig. 2B).
ngraftment. Cell engraftment was assessed by immuno-
istochemical analysis of the skeletal muscle-specific marker
skMyHC (Fig. 3B, green). The majority of engrafted
uman cell-derived myocytes had aligned with the host
yocardial fibers and along the ischemic border zone and
car area (Figs. 3A and 3B). Interestingly, the CD56
yogenic cells regenerated less fskMyHC myofibers when
ompared with the CD34CD144 endothelial cells (Fig.
C). Compared with both of these groups, the CD56
D34CD144 myoendothelial cells regenerated signifi-
antly more skeletal myofibers (p  0.05, myoendothelial
ells vs. myogenic cells, endothelial cells) (Fig. 3C), indi-
ating that these cells have an efficient transplantation
apacity, as observed in skeletal muscle (18). Heart sections
ere also costained with antibodies directed against human-
pecific PCNA and fskMyHC (Fig. 3D). A few nuclei
blue) in the fskMyHC engraftment region (green) ex-
ressed PCNA (red). This finding confirms the presence of
uman cells within the fskMyHC engraftment region, and
uggests that a fraction of myoendothelial cells are prolifer-
tive for up to 2 weeks after implantation.
valuation of cardiac differentiation. In hearts injected
ith nLacZ-transduced myoendothelial cells, we evaluated
hether any donor cells colocalized with the cardiac-specific
soforms of troponin I and troponin T (cTnT) and the gap
unction protein connexin43, a protein essential for inter-
ellular electrical connections between cardiomyocytes
14,15). We observed only a few cells containing nLacZ
uclei that colocalized with cTnI (Figs. 3E to 3H) and
TnT (Figs. 3I to 3L). However, the vast majority of
LacZ cells did not colocalize with these cardiac markers.
n addition, we did not observe expression of connexin43 at
he interface of the graft and host myocardium, suggesting
hat engrafted cells were electrically isolated from host
ardiomyocytes. Connexin43 gap junction proteins were not
xpressed by donor cells within the graft.
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ue was assessed by CD31 (platelet endothelial cell adhesion
olecule) immunostaining (Fig. 4A, red). Intramyocardial
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December 2, 2008:1869–80 Cardiomyoplasty Via Human Stem Cellsyoendothelial cells induced the greatest increase of capil-
aries in the infarct area (p  0.05, myoendothelial cells vs.
yogenic cells and endothelial cells) (Fig. 4B), which was
ollowed by endothelial cells and myogenic cells, respec-
ively. These findings suggest that each transplanted cell
opulation had an angiogenic effect; however, myoendothe-
ial cells were the most effective at stimulating angiogenesis.
ndogenous cardiomyocyte proliferation and apoptosis.
e have assessed host cardiomyocyte proliferation and
poptosis at 5 days and 6 weeks after MI. Five days after
I, we observed numerous proliferating endogenous cells
ocated at the infarct border zone. We observed no differ-
nce among the groups for the total number of Ki-67–
ositive cells at the peri-infarct zone (myoendothelial cells
8  10 Ki-67 cells, n  3 hearts; endothelial cells 63 
6, n  4; myogenic cells 63  12, n  3; saline control 60
5, n  4; p  0.859). We also measured the number of
ells that coexpressed both Ki-67 and cTnI within the
eri-infarct region (Figs. 5A to 5C). Five days after cell
ransplantation, hearts injected with myoendothelial cells
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Figure 2 Injection of Myoendothelial Cells Reduces
Scar Tissue Formation After Myocardial Infarction
(A) Representative images taken from transverse sections of the left ventricle
stained by Masson’s trichrome (muscle is stained red, collagen is stained
blue). The hearts injected with CD56CD34CD144 cells displayed smaller
infarct scar areas than did the control hearts injected with phosphate-buffered
saline (PBS) only. Scale bars  1 mm. (B) Compared with all groups, the CD56
CD34CD144 cell-injected hearts had the smallest scar tissue area 2 and 6
weeks after infarction (*p  0.05, CD56CD34CD144 cells vs. PBS).ad more proliferating Ki-67()/cTnI() cardiomyocytes m13 4 cardiomyocytes) within the infarct border zone than
earts injected with either endothelial cells (3  1), myo-
enic cells (2  1), or saline (3  1) (p  0.05, myoendo-
helial cells vs. myogenic cells, endothelial cells, and PBS)
Fig. 5C). Six weeks after cell transplantation, in hearts
njected with CD56 myogenic cells (1  1) and CD34
D144 endothelial cells (2  1), the number of prolifer-
ting endogenous cTnI cardiomyocytes was comparable to
ontrol hearts injected with PBS (1  1) 6 weeks after MI
Fig. 5C). However, endogenous cardiomyocyte prolifera-
ion was the highest in hearts injected with myoendothelial
ells (6  1) (p  0.05, myoendothelial cells vs. myogenic
ells, endothelial cells, and PBS) (Fig. 5C).
We performed multilabel staining for DNA end-labeling
y TUNEL and cTnI to determine the effect of cell therapy
n endogenous cardiomyocyte apoptosis in the peri-infarct
egions. At 5 days after MI, the occurrence of apoptotic
ardiomyocytes within the peri-infarct regions was less
requent in hearts injected with myoendothelial cells (7  1
UNEL cardiomyocytes) when compared with the trans-
lantation of PBS (27  6), myogenic cells (20  3), and
ndothelial cells (14 2) (p 0.05, myoendothelial cells vs.
BS) (Fig. 5D). By 6 weeks after cell transplantation, the
umber of apoptotic cardiomyocytes decreased consider-
bly. Hearts injected with all 3 cell types had slightly fewer
poptotic cardiomyocytes in the peri-infarct regions when
ompared with hearts receiving transplantation of PBS only
p  0.05 myoendothelial cells vs. PBS) (Fig. 5D). Taken
ogether, these results suggest that the transplantation of
yoendothelial cells had a beneficial effect on endogenous
ardiomyocyte proliferation and apoptosis, with the most
arked effect occurring shortly after implantation.
nalysis of paracrine factors. For all 3 populations, we
sed qPCR to measure the expression of secretable factor
enes, including vascular endothelial growth factor
Vegf165), hepatocyte growth factor (Hgf) (25–27), insulin-
ike growth factor-I (Igf-I), and basic fibroblast growth
actor (b-Fgf). All of these factors are known to act as
herapeutic agents in the heart (28,29). Under normal
ulture conditions, we observed expression of Vegf165, Hgf,
nd Igf-I genes from myoendothelial cells of first donor
ample. There was no detectable expression of the b-Fgf
ene (Fig. 6A). Interestingly, while the Hgf gene was
xpressed in CD56CD34CD144 cells (myoendothe-
ial) (Fig. 6A), we did not observe measurable expression in
D56CD34CD144 (myogenic) and CD56CD34
D144 (endothelial) cells (data not shown). Hypoxic
onditions stimulated a 4.4-fold increase in Vegf165 gene
xpression by myoendothelial cells. In contrast, the expres-
ion of Hgf and Igf-I genes decreased upon exposure to
ypoxia, and b-Fgf gene expression remained undetectable
Fig. 6A). Of note, Vegf165 gene expression was considerably
igher when compared with other analyzed factors (Fig.
A), suggesting that VEGF may represent a major factor
ecreted by myoendothelial cells, as previously observed with
urine MDSCs (21). All 3 populations increased Vegf165
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oxia (p  0.01, normoxia vs. hypoxia) (Fig. 6B). The
egf165 mRNA results were further confirmed by ELISA
here all tested cell types had at least a 4-fold increase in
EGF protein secretion under hypoxic conditions when
ompared with that in control normoxic conditions (p 
.05, normoxia vs. hypoxia) (Fig. 6C). Although only a few
actors were analyzed here, our findings suggest that myo-
ndothelial cells secrete factors, especially when subjected
o ischemic conditions, which may have therapeutic effect
n vivo.
n vivo VEGF expression. We evaluated whether human
EGF was expressed in vivo. Using an antibody that is
pecific for human VEGF, we observed human VEGF
xpression within cell-injected hearts 5 days after MI
 




	
Figure 3 Engraftment of Human Muscle-Derived Cells in the Inf
(A) Masson’s trichrome staining (muscle is stained red, collagen is stained blue) at th
transplantation. Scale bar equals 500 m. The dotted line shows the engraftment are
chain-positive (green) immunostaining. In the image, the fast skeletal myosin heavy c
I-positive cardiomyocytes are stained red. Only the engraftment regions expressed fas
heavy chain. Scale bar  50 m. (C) CD56CD34CD144 myoendothelial cells reg
CD144 myogenic and CD56CD34CD144 endothelial cells (*p  0.05). (D) A fe
area stained positive for human-specific proliferating cell nuclear antigen (red, arrows)
cells in vivo. (E) Engrafted myoendothelial cells expressing the nLacZ reporter gene (b
diamidino-2-phenylindole-only (G, blue, arrow) and colocalized with troponin I (H, pink
cardiac troponin T marker (green, arrowhead). DAPI-only (K, blue, arrow) and colocalidata not shown). Engrafted nLacZ-tranduced donor mells were found to colocalize with human VEGF (data
ot shown).
iscussion
atellite cells, which are myogenic progenitor cells located
eneath the basal lamina of skeletal myofibers, are known to
eside in close proximity to capillaries (30). A developmental
elationship between satellite cells and endothelial cells,
esides their spatially close proximity in skeletal muscle, has
een suggested by Tamaki et al. (16), who have documented
he presence of myogenic progenitor cells that coexpress
arkers associated with the myogenic and endothelial
ineages within the interstitial spaces of murine skeletal
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December 2, 2008:1869–80 Cardiomyoplasty Via Human Stem Cellsrogenitors originating from the embryonic dorsal aorta has
ed to the notion that a subset of satellite cells may have a
ascular origin (17). Our research has resulted in the
dentification and isolation of progenitor cells residing
ithin adult human skeletal muscle that coexpress myogenic
nd endothelial cell markers (18). These myoendothelial
ells also demonstrated a potent regenerative capacity when
ransplanted into injured skeletal muscles (18), indicating
hat they may yield a better therapeutic promise than
yoblasts.
The main finding in this study is that transplantation of
uman myoendothelial cells attenuated LV dysfunction more
ffectively than either myogenic or endothelial cells in an acute
I. At the 6-week time point, cardiac contractility in the
yoendothelial cell-injected hearts was 40% and 50% greater
ompared with that in hearts injected with either endothelial
ells or myogenic cells, respectively. The improved therapeutic
enefit elicited by the injection of myoendothelial cells could be
t least partially explained by the reduced levels of scar tissue
nd apoptotic cardiomyocytes and the increased levels of
ngraftment, angiogenesis, and endogenous cardiomyocyte
roliferation when compared with that observed with myo-
enic and endothelial cells.
A key goal of cardiac cell transplantation for myocardial
nfarct repair is to modify LV remodeling in order to
ncrease functional repair. Despite the fact that all 3 cell
ypes did not prevent LV dilation compared with PBS
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CD144 cells, and CD56CD34CD144 cells. Scale bars  100 m. (B) Heart
the infarct when compared with the other groups (*p  0.05, CD56CD34CD14
vs. phosphate-buffered saline [PBS]).ontrol, myoendothelial cells significantly reduced LV in- (arct size and sustained LV contractile function better than
he other 2 cell types and PBS. It remains to be investigated
f the beneficial effects of myoendothelial cells will reduce
V dilation at longer time points.
Our histological analysis demonstrated a higher level of
ngraftment based on the number of regenerated myofibers
n myoendothelial cell-injected hearts when compared with
he other cell-injected hearts. Because there is a correlation
etween the magnitude of functional improvement and
onor cell engraftment (31–33), the large degree of engraft-
ent of myoendothelial (CD56CD34CD144) cells is a
ood indicator of their enhanced ability to improve cardiac
unction. This superior engraftment is likely related to the
uperior survival characteristics of myoendothelial cells, as
bserved in skeletal muscle (18), which could be due to their
nhanced ability to resist oxidative stress compared with
yogenic and endothelial cells. This same enhanced sur-
ival characteristic was also observed with murine MDSCs,
hich were found to be more resistant to oxidative stress
han SkMs (14).
A few of the injected myoendothelial cells were observed
o express cardiac cell markers within the infarcted heart.
he frequency of this event was quite rare as the vast
ajority of engrafted donor cells were negative for cTnI and
TnT. It is undetermined from these experiments whether
hese cardiac marker-expressing donor cells originated from
ifferentiation or fusion with the host cardiomyocyte
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Cardiomyoplasty Via Human Stem Cells December 2, 2008:1869–80All 3 cell populations had an angiogenic effect upon
ransplantation, a finding that is consistent with many
eports in the field (1,14,20,35–37). Neovascularization of
he infarct may help to salvage at-risk myocardium by
romoting endogenous cell survival and proliferation, stim-
lating hibernating myocardium, enhancing scar viability,
nd attenuating adverse remodeling (20). When we previ-
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Figure 5 Endogenous
Cardiomyocyte Proliferation and Apoptosis
(A and B) Proliferating cardiomyocytes within the peri-infarct region were identi-
fied by colocalization of both Ki-67 (purple nuclear stain, arrow) and cardiac
troponin I (cTnI) (brown cytoplasmic stain) within the peri-infarct region (arrow).
Some of the proliferating cells stained by Ki-67 exist within the infarct zone,
but do not colocalize with cTnI (arrowhead). Scale bars  50 m. (C) The
number of endogenous proliferating cardiomyocytes was higher in the peri-in-
farct region of the heart injected with CD56CD34CD144 cells compared
with that seen in other groups at both 5 days and 6 weeks after cell transplan-
tation (*p  0.05, CD56CD34CD144 cells vs. CD56CD34CD144
cells, CD56CD34CD144 cells, and phosphate-buffered saline [PBS]). (D)
The number of apoptotic cardiomyocytes was measured at both 5 days and 6
weeks after myocardial infarction (†p  0.05, CD56CD34CD144 cells vs.
PBS). HPF  high-power fields; TUNEL  terminal dUPT nick end-labeling.usly reported on the intramyocardial injection of MDSCs,*
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Figure 6 Growth Factor Expression In Vitro
(A) An increase in vascular endothelial growth factor (Vegf165) mRNA produc-
tion by CD56CD34CD144 cells was observed when cultured under hypoxia
for 24 h in comparison with that seen in control normoxic conditions. In con-
trast, hepatocyte growth factor (Hgf), basic fibroblast growth factor (b-Fgf), and
insulin-like growth factor-I (Igf-I) mRNA expression by human CD56CD34
CD144 cells either significantly decreased or was not detectable after 24 h of
hypoxia. (B) All cell types greatly increased their secretion of Vegf mRNA after
exposure to hypoxic culture conditions for 24 h when compared with control
cells in normoxia culture conditions by quantitative polymerase chain reaction
analysis of Vegf mRNA expression (*p  0.01, normoxia vs. hypoxia). (C)
These results were further confirmed by VEGF ELISA analysis (*p  0.05, nor-
moxia vs. hypoxia).
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December 2, 2008:1869–80 Cardiomyoplasty Via Human Stem Cellse observed that most of the new vasculature that formed
ithin the infarct was of host origin. The occurrence of
ransplanted murine MDSCs differentiating into blood
essels was rare (14,15), indicating that the presence of new
asculature within the infarct may be due to paracrine
actors. Likewise, in this study, we found that only a few
onor cells had incorporated into the neovasculature, as
videnced by our use of a human-specific CD31 antibody
data not shown), suggesting that the new capillaries are of
ost-origin and may be induced by a paracrine factor
eleased by the donor cells. In a recent study, we reported
hat one of the most potent angiogenic factors, VEGF, may
e critical for the occurrence of angiogenesis in murine
DSC-treated hearts (21). Overall, the ability of myoen-
othelial cells to induce the greatest level of angiogenesis
ithin the infarct may be a major factor underlying their
herapeutic effect.
Recent reports have demonstrated that a population of
yocytes within the myocardium is capable of proliferating
fter infarction (38,39). Schuster et al. (40) report that
yocardial neovascularization results in regeneration and
ell cycling of endogenous cardiomyocytes, suggesting that
gents that increase myocardial homing of bone marrow
ngioblasts could induce endogenous cardiomyocytes to
nter the cell cycle and improve functional cardiac recovery.
e observed that mouse cardiomyocytes located within the
eri-infarct region in animals receiving human myoendo-
helial cells demonstrated much higher mitotic activity than
n those receiving PBS at 5 days after cell transplantation.
he origin of these proliferating cells remains unknown, but
hey could originate from resident cardiomyocytes, differ-
ntiating cardiac stem cells, or from circulating stem cells
hat home to the myocardium after infarction (39).
Additionally, TUNEL staining showed reduced levels of
poptosis, suggesting that myoendothelial (CD56CD34
D144) cell transplantation was effective at reducing
ndogenous cardiomyocyte apoptosis at the initial phase
fter MI.
Transplanted cells may have a beneficial paracrine effect
n the heart by releasing growth factors that promote
ngiogenesis, cell proliferation, antiapoptosis, antifibrotic
ffects, and cardioprotective effects (40,41). Although we
nly evaluated the expression of a few secretable factors,
PCR analysis showed that VEGF and HGF are 2 factors
ecreted by transplanted human muscle cells in response
o the ischemic microenvironment of the infarcted hearts.
e observed elevated HGF expression in myoendothelial
CD56CD34CD144) cells but not in the other tested
ell populations. It has been previously demonstrated that
GF can greatly increase myogenic regeneration and vas-
ularity while reducing fibrosis inside the graft, which
nhances the efficacy of SkM transplantation to infarcted
earts (25). Of all the factors evaluated, VEGF was the only
actor to significantly increase upon exposure to hypoxic
ulture conditions. Since the cells are transplanted into an
schemic environment, VEGF may be highly secreted by theonor cells and be a major factor in the induction of
ngiogenesis and promotion of endogenous cell survival
1,21,37). In addition, VEGF and HGF may have a
ynergistic effect resulting in a more robust proliferative,
hemotactic, and angiogenic response than either growth
actor alone (42,43).
Here, we have shown that human skeletal muscle-derived
yoendothelial (CD56CD34CD144) cells represent a
nique cell population with a superior ability for myocardial
nfarct repair when compared with conventional myogenic
r endothelial cells, as recently observed in skeletal muscle
18). Based on the results presented here, the beneficial
herapeutic outcomes of myoendothelial cell transplanta-
ion, including the improvement of cardiac function, atten-
ation of adverse cardiac remodeling, cardioprotection of
t-risk endogenous cardiac cells, and the stimulation of both
nfarct neovascularization and endogenous cell proliferation,
ay emanate from the robust engraftment of myoendothe-
ial cells.
onclusions
yoendothelial cells represent a unique population of
rogenitor cells from human skeletal muscle that may be
imilar to murine MDSCs (14) in regard to the therapeutic
epair of skeletal (18) and cardiac muscles.
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